<h4>Background</h4>Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), demonstrates significant efficacy in treating non-small cell lung cancer (NSCLC) harboring sensitive EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.